Paul S Jellinger

Summary

Publications

  1. ncbi request reprint Metabolic consequences of hyperglycemia and insulin resistance
    Paul S Jellinger
    The Center for Diabetes and Endocrine Care, Voluntary Faculty, University of Miami, Hollywood, Florida 33201, USA
    Clin Cornerstone 8:S30-42. 2007
  2. doi request reprint Focus on incretin-based therapies: targeting the core defects of type 2 diabetes
    Paul S Jellinger
    University of Miami, Miami, FL, USA
    Postgrad Med 123:53-65. 2011
  3. ncbi request reprint American College of Endocrinology position statement on the insulin resistance syndrome
    Daniel Einhorn
    American College of Endocrinology
    Endocr Pract 9:237-52. 2003
  4. ncbi request reprint Emerging concepts in management of the insulin resistance syndrome
    Paul S Jellinger
    Endocr Pract 9:105-12. 2003
  5. ncbi request reprint ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations
    Harold E Lebovitz
    Endocr Pract 12:6-12. 2006
  6. ncbi request reprint Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Nathan et
    Paul S Jellinger
    Diabetes Care 30:e16-7; author reply e18-20, e21-2. 2007
  7. ncbi request reprint Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force
    Paul S Jellinger
    Endocr Pract 13:260-8. 2007

Detail Information

Publications7

  1. ncbi request reprint Metabolic consequences of hyperglycemia and insulin resistance
    Paul S Jellinger
    The Center for Diabetes and Endocrine Care, Voluntary Faculty, University of Miami, Hollywood, Florida 33201, USA
    Clin Cornerstone 8:S30-42. 2007
    ..Pharmacotherapies that target IR include metformin and the thiazolidinediones. Endocannabinoid antagonists, agents that target obesity and associated cardiovascular and metabolic risk factors, are currently being developed...
  2. doi request reprint Focus on incretin-based therapies: targeting the core defects of type 2 diabetes
    Paul S Jellinger
    University of Miami, Miami, FL, USA
    Postgrad Med 123:53-65. 2011
    ..Information was obtained by a search of the PubMed and MEDLINE databases for articles published from January 1, 1995 to June 1, 2009...
  3. ncbi request reprint American College of Endocrinology position statement on the insulin resistance syndrome
    Daniel Einhorn
    American College of Endocrinology
    Endocr Pract 9:237-52. 2003
  4. ncbi request reprint Emerging concepts in management of the insulin resistance syndrome
    Paul S Jellinger
    Endocr Pract 9:105-12. 2003
  5. ncbi request reprint ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations
    Harold E Lebovitz
    Endocr Pract 12:6-12. 2006
  6. ncbi request reprint Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes: response to Nathan et
    Paul S Jellinger
    Diabetes Care 30:e16-7; author reply e18-20, e21-2. 2007
  7. ncbi request reprint Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force
    Paul S Jellinger
    Endocr Pract 13:260-8. 2007